Lipella Pharmaceuticals
(OTC) LIPO
Lipella Pharmaceuticals Financials at a Glance
Market Cap
$369.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$173.67K
Net Income (TTM)
-$5.33M
EPS (TTM)
-$2.41
P/E Ratio
-0.03
Dividend
$0.00
Beta (Volatility)
0.31 (Low)
Dividend
$0.00
Beta (Volatility)
0.31 (Low)
Price
$0.08
Volume
104,203
Open
$0.12
Price
$0.08
Volume
104,203
Open
$0.12
Previous Close
$0.08
Daily Range
$0.05 - $0.12
52-Week Range
$0.02 - $0.94
Estimated Earnings Date
Jun 3, 2026
Dividend
$0.00
Beta (Volatility)
0.31 (Low)
Price
$0.08
Volume
104,203
Open
$0.12
Previous Close
$0.08
Daily Range
$0.05 - $0.12
52-Week Range
$0.02 - $0.94
Estimated Earnings Date
Jun 3, 2026
LIPO News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Lipella Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
7
CEO
Jonathan Kaufman, PhD, MBA
Website
www.lipella.comHeadquarters
Pittsburgh, PA 15208, US
LIPO Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-140.39%
Return on Capital
-258.28%
Return on Assets
-165.46%
Earnings Yield
-33.33%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$369.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
4.62M
Volume
104.20K
Avg. Volume
37.33K
Financials (TTM)
Gross Profit
-$3.39M
Operating Income
-$5.41M
EBITDA
-$5.33M
Operating Cash Flow
-$2.36B
Capital Expenditure
$0.00
Free Cash Flow
-$2.36B
Cash & ST Invst.
$1.86M
Total Debt
$264.08K
Lipella Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$720.97K
+31.1%
Gross Margin
0.00%
N/A
Market Cap
$369.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$73.94K
N/A
Employees
5
N/A
Net Income
-$1.25M
+13.2%
EBITDA
-$1.25M
+13.2%
Quarterly Fundamentals
Total Cash
$1.86M
+37.1%
Total Debt
$264.08K
+272.8%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$219.82K
N/A
Short Term Debt
$44.27K
-37.5%
Return on Assets
-1.65%
N/A
Return on Invested Capital
-2.32%
N/A
Free Cash Flow
-$2.36B
-360909.2%
Operating Cash Flow
-$2.36B
-360909.2%